Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Verastem Oncology revenue
Verastem Oncology's revenue is $10.0 million.
What is Verastem Oncology's revenue?
- Verastem Oncology's revenue growth from 2018 to 2024 is -62.57%.
- Verastem Oncology has 150 employees, and the revenue per employee ratio is $66,666.
- Verastem Oncology's peak quarterly revenue was $78.6M in 2020(q3).
- Verastem Oncology peak revenue was $88.5M in 2020.
- Verastem Oncology annual revenue for 2022 was 2.6M, 26.45% growth from 2021.
- Verastem Oncology annual revenue for 2024 was 10.0M, 285.21% growth from 2022.
On this page
Zippi applies for you, and finds you a job.
Verastem Oncology historical revenue
Verastem Oncology's peak revenue was $88.5M in 2020. The peak quarterly revenue was $78.6M in 2020(q3).
Verastem Oncology's revenue increased from $26.7m in 2018 to $10.0M currently. That's a -62.57% change in annual revenue.
Verastem Oncology annual revenue
Verastem Oncology annual revenue over time
| Fiscal year / year | Verastem Oncology revenue |
|---|---|
| 2018 | $26.7M |
| 2019 | $17.5M |
| 2020 | $88.5M |
| 2021 | $2.1M |
| 2022 | $2.6M |
| 2024 | $10.0M |
Rate Verastem Oncology's financial transparency
Verastem Oncology annual growth
Verastem Oncology saw the greatest revenue growth in 2020, when revenue increased by 407.08%.
Verastem Oncology had the lowest revenue growth in 2021, when revenue changed by -97.68%.
Verastem Oncology annual growth rate over time
| Year | Verastem Oncology growth |
|---|---|
| 2019 | -35%↓ |
| 2020 | 407%↑ |
| 2021 | -98%↓ |
| 2022 | 26%↑ |
| 2024 | 285%↑ |
Verastem Oncology quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Verastem Oncology quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2018 | - | $10.0M | $15.5M | $1.2M |
| 2019 | $1.7M | $3.1M | $9.0M | $3.6M |
| 2020 | $5.1M | $4.3M | $78.6M | $506,000 |
| 2021 | $1.0M | $500,000 | $2,000 | $545,000 |
| 2022 | $2.6M | - | - | - |
| 2024 | - | $10.0M | - | - |
Verastem Oncology jobs nearby
Do you work at Verastem Oncology?
Is Verastem Oncology transparent about its revenue structure?
Verastem Oncology financial information
| CEO | Brian M. Stuglik |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 150 |
| Date Founded | 2010 |
| Headquarters | Needham, Massachusetts |
| Number of Locations | 1 |
| Revenue | $10.0M |
| Net Income | -$73,812,000 |
| Gross Proft | $54.8M (2020) |
| PE Ratio | -1.82 |
| Tax Rate | -0.0% |
| Market Capitalization | $237.6M |
| Total Assets | $95,050,000 |
| Ticker | VSTM |
Verastem Oncology jobs you might like
Verastem Oncology financing
Verastem Oncology received early financing of $16.0M on 2010-11-16.
| Series | Round size | Date |
|---|---|---|
| Series A | $16M | 11/2010 |
| Series B | $32M | 07/2011 |
| Series C | $20M | 11/2011 |
| Post Ipo Equity | $2M | 07/2012 |
| Post Ipo Debt | $25M | 03/2017 |
| Post Ipo Equity | $100M | 02/2020 |
| Post Ipo Debt | $25M | 03/2022 |
Verastem Oncology investors
| Investors | Security type |
|---|---|
| Longwood Fund | Series A |
| Cardinal Partners | Series A |
| MPM Capital | Series A |
| Bessemer Venture Partners | Series A |
| Longwood Fund | Series B |
| Astellas Venture Management LLC | Series B |
| Cardinal Partners | Series B |
| MPM Capital | Series B |
| Bessemer Venture Partners | Series B |
| Advanced Technology Ventures | Series B |
| Longwood Fund | Series C |
| Cardinal Partners | Series C |
| MPM Capital | Series C |
| Bessemer Venture Partners | Series C |
| HERCULES CAPITAL INC | Post Ipo Debt |
| Oxford Finance LLC | Post Ipo Debt |
Verastem Oncology competitors
Verastem Oncology's top competitor, Merck, earned an annual revenue of $64.2B.
Verastem Oncology's smallest competitor is Immunomedics with revenue of $21.5M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Vertex Pharmaceuticals | $95,952 | $11.0B | 3,400 | 104 |
| Med Immune Inc | $56,355 | $1.7B | 5,000 | - |
| Immunomedics | $81,050 | $21.5M | 185 | - |
| Merck | $90,328 | $64.2B | 74,000 | 1,709 |
| Regeneron | $85,589 | $14.2B | 9,123 | 268 |
| Amgen | $93,349 | $33.4B | 22,000 | 460 |
| Gilead Sciences | $99,828 | $28.8B | 11,800 | 459 |
| Sarepta Therapeutics | $94,985 | $1.9B | 840 | 18 |
| Amneal Pharmaceuticals | $76,227 | $2.8B | 6,500 | 105 |
| PTC Therapeutics | $92,986 | $806.8M | 517 | 14 |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Verastem Oncology highest paying jobs
Zippia gives an in-depth look into the details of Verastem Oncology, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Verastem Oncology. The employee data is based on information from people who have self-reported their past or current employments at Verastem Oncology. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Verastem Oncology. The data presented on this page does not represent the view of Verastem Oncology and its employees or that of Zippia.
Verastem Oncology may also be known as or be related to VERASTEM INC., Verastem, Verastem Inc, Verastem Oncology and Verastem, Inc.